| Drug May Impede Thyroid Cancer A study of an experimental AstraZeneca drug, vandetanib, showed it delayed the progression of a rare type of thyroid cancer. online.wsj.com |
Medtronic Works to Fix Defibrillators on Battery Problem Medtronic Inc.'s Physio-Control subsidiary said Friday it recently launched a field correction effort to fix certain devices used to shock patients in cardiac arrest because it found a potential battery-power problem, and that one patient may have died as a result. online.wsj.com |
Stem Cell Competition Heating Up Michael Becker submits:According to the National Institutes of Health’s [NIH] stem cell primer, stem cells have the ability to develop into many different cell types in the body during early life and growth. In many tissues they serve as an internal repair system, dividing essentially without limit to replenish other cells. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell. For an industry segment known for both hope and hype, it is no surprise that stem cell therapies are once again making headlines. On July 30, 2010, the U.S. Food and Drug Administration [FDA] lifted the clinical hold on Geron Corporation’s (GERN) Phase I trial using its embryonic stem cell-based therapy for the treatment of patients with acute spinal cord injury. Within days of the news, shares of Geron increased more than 30%, going from $4.80 to $6.39.Complete Story » seekingalpha.com |
20 Biotech Stocks Targeted by Short Sellers Over the Last 3 Months Kapitall submits:The following is a list of biotech stocks that are being targeted by short sellers. All of these stocks have seen significant increases in their short ratios between the end of May and the end of August. The short ratio expresses the total number of shares shorted as a multiple of the stock's average daily volume. Complete Story » seekingalpha.com |
Latest Developments in the Pharmathene-SIGA Case Point to a Strong Buy for PIP James Altucher submits:There’s been significant developments in the PIP-SIGA case since my last article (written when PIP was at $1.90) and I wanted to both summarize them and also establish some facts that seem to be points of confusion on the various message boards out there: Fact: SIGA has tried twice now to dismiss the case or portions of the case (note that this most recent attempt was an attempt at a partial dismissal) and twice the judge has ruled that this is going to trial. The second dismissal was predicted in my first article.Complete Story » seekingalpha.com |